Butyrylcholinesterase Inhibitor Screening Kit (Colorimetric)

MILPITAS, Calif. - May 5, 2021 - PRLog -- Butyrylcholinesterase, also known as BChE, BuChE, pseudocholinesterase, or plasma esterase is a cholinesterase enzyme that is mainly made in the liver and is present in blood plasma. It is a non-specific enzyme that hydrolyses various choline-based esters. It is also a physiological regulator of ghrelin signaling. BChE activity in plasma serves as a liver function test as both hypercholinesterasemia and hypocholinesterasemia indicate pathological processes. Additionally, reversible inhibitors of BChE such as rivastigmine, tacrine, and galantamine are commonly used in the treatment of Alzheimer's disease and other neurodegenerative disorders. However, irreversible inhibition of BChE tends to be extremely poisonous, causing muscular paralysis, convulsions, bronchial constriction, and eventually death by asphyxia.

BioVision's Butyrylcholinesterase Inhibitor Screening Kit is a 96-well plate based, colorimetric assay to screen potential inhibitors of BChE. The kit utilizes the ability of active human BChE enzyme to hydrolyze the BChE substrate thereby generating a yellow colored product measured by absorbance at 412 nm. As the enzyme activity is inhibited in the presence of a potent, reversible BChE inhibitor, Rivastigmine, the color formation is inhibited. The assay is adapted for a 96-well plate format and provides a rapid, simple, and reliable test for high-throughput screening of BChE inhibitors.

Figure: Inhibition of BChE activity by Rivastigmine. IC50 of Rivastigmine was calculated to be 550.9 ± 120.2 nM. Assay was performed following the kit protocol.

For more information on this assay kit Cat# K2084, Visit: https://bit.ly/3ur1Mx2